Pay in 4 interest-free payments of $6.03 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
J Cell Physiol 230:30093018 Yu J, Shi YC, Ping F, Li W, Zhang HB, He SL, Zhao Y, Xu LL, Li YX (2021) Liraglutide inhibits osteoclastogenesis and improves bone loss by downregulating Trem2 in female type 1 diabetic mice: findings from transcriptomics
VK0214, oral TR agonist for X-linked adrenoleukodystrophy (X-ALD) Recent Highlights: In June 2026, Viking announced that its working toward maintenance-dosing data for subcutaneous VK2735 and preparing to start Phase 3 trials of the oral tablet in Q4 2026, with the goal of becoming the first company to offer a dual GLP-1/GIP agonist in both oral and injectable form
Intentional and unintentional nonadherence: a study of decision making
However, few studies have investigated the dose-dependent features of dynamic glucose metabolism including glucose dose sensitivity and response time after glucose administration in vivo across various types of metabolic regulation 19,20
US$ 27.23
US$ 28.77
US$ 28.90
US$ 23.66
US$ 28.58
US$ 21.78
US$ 21.81
US$ 22.01
US$ 28.70
US$ 26.17
